Get started

Bullish Pennant

## CreditAccess Grameen (CREDITACC) Share Price Analysis- As of May 2, 2025, CreditAccess Grameen (CREDITACC) traded around ₹1,121–₹1,145, which is approximately 52% above its 52-week low of ₹750.20 (set in January 2025), but below its 52-week high of ₹1,551.95 (set in June 2024) . - The stock has shown volatility over the past year, with a notable decline from its peak, reflecting both sector trends and company-specific events . **Valuation and Financial Metrics** - **P/E Ratio (TTM):** 20.3–21.2, indicating moderate valuation relative to earnings . - **Book Value:** ₹438 per share, with the stock trading at about 2.6 times book value, which is considered on the higher side for the sector . - **Dividend Yield:** Around 0.86–0.89%, with recent dividend payouts . - **Return on Equity (ROE):** 24.8% (latest year), reflecting strong profitability . - **Return on Capital Employed (ROCE):** 14.8% . **Growth and Profitability** - The company has delivered robust profit growth (35% CAGR over the last 5 years) and strong median sales growth (31.6% over 10 years) - However, profit growth has turned negative in the trailing twelve months (-35%), primarily due to higher provisioning and write-offs in recent quarters - The company reported a loss of ₹99.5 crore in Q3 FY25, mainly due to early risk recognition, conservative provisioning, and accelerated write-offs, but management expects this to safeguard future profitability as growth normalizes **Operational Highlights** - **Assets Under Management (AUM):** Grew by 6.1% YoY to ₹24,810 crore in Q3 FY25 - **Borrower Base:** Increased by 2.4% YoY to 48.05 lakh customers - **Branch Network:** Expanded by 8.7% YoY to 2,059 branches - **Collection Efficiency:** Remained robust at 93.3% (excluding arrears) and 94.1% (including arrears), with improving trends - **Asset Quality:** PAR 90+ at 2.64%, NNPA at 1.28%, indicating some stress but manageable levels - **Capital Adequacy:** CRAR at 25.9%, reflecting a strong capital position **Strengths and Risks** **Strengths:** - Consistent long-term growth in profits and sales - Strong capital position and liquidity buffer - High collection efficiency and expanding branch network **Risks/Concerns:** - Recent decline in promoter holding (-7.42% over three years) - Low interest coverage ratio, suggesting higher financial risk - Elevated provisioning and write-offs impacting near-term profitability - Stock is trading at a premium to book value, which may limit upside if growth slows **Relative Performance** - Over the past year, the stock is down 24%, underperforming the broader market, but over five years, it has delivered a 154% return, broadly in line with sector peers - In the short term (last three months), the stock has rebounded by about 13% from its lows ## Summary CreditAccess Grameen remains a leading NBFC-MFI with a strong track record of growth and profitability. While recent quarters have seen a dip in profits due to prudent risk management and provisioning, the company’s fundamentals-such as robust capital adequacy, liquidity, and operational scale-remain intact. The stock is moderately valued but carries risks related to asset quality and sector volatility. Investors should watch for normalization of growth and profitability in upcoming quarters, as indicated by management
NSE:CREDITACCLong
by KarniKripaa
ERIS Lifesciences Share Price AnalysisEris Lifesciences is currently trading in the range of ₹1,371 to ₹1,474, with the latest reported price at ₹1,474.20 as of April 23, 2025. The stock has shown strong performance over the past year, delivering a return of approximately 57%. Over the last three months, the stock is up about 9%, though it has seen a slight dip of 0.57% in the past month. **Valuation and Fundamentals** Eris Lifesciences trades at a price-to-earnings (P/E) ratio of 57.13, which is high for the sector, and a price-to-book (P/B) ratio of 4.53. The company’s earnings per share (EPS) stands at 29.19, and its return on equity (ROE) is 12.63%, indicating moderate profitability. The market capitalization is approximately ₹18,831 crore . The dividend yield is negligible, suggesting the company focuses more on growth than on returning cash to shareholders. **Analyst Sentiment and Targets** Analyst sentiment is strongly positive, with nearly 89% recommending a buy and the remainder suggesting hold; there are no sell recommendations. The average long-term price target from analysts is ₹1,512.56, indicating modest upside from current levels. **Technical and Trading Overview** The stock has recently traded near its upper circuit of ₹1,659.60, with a lower circuit at ₹1,106.40, reflecting a relatively wide trading band and potential for volatility. Recent trading volumes have been healthy, supporting the current price momentum. **Summary** Eris Lifesciences has delivered strong returns over the past year and is viewed positively by analysts. However, its high P/E ratio suggests the stock is priced for continued growth, and the lack of dividend yield may not appeal to income-focused investors. The technical outlook is stable, with the stock trading near its highs and supported by robust trading activity.
NSE:ERISLong
by KarniKripaa
NTPC price analysisNTPC is currently trading around ₹360, having shown a modest gain of about 4% over the past year. The stock reached its all-time high of ₹448.45 in September 2024 and has since pulled back, with recent price action reflecting some consolidation after a strong multi-year rally . Over the last month, NTPC has delivered a positive return of approximately 2.5%, indicating some short-term strength despite a slight decline of nearly 1.8% in the past week. Fundamentally, NTPC remains a large-cap, stable utility with a market capitalization near ₹3.5 lakh crore and a price-to-earnings (PE) ratio of about 15.9, which is below the industry average, suggesting reasonable valuation. The company boasts a healthy dividend yield of 2.5%, and its return on equity (ROE) stands at 13.1%. Promoter holding remains steady at 51.1%, and the company continues to report strong profits, with net profit for the latest fiscal year exceeding ₹20,000 crore. Analyst sentiment is generally positive, with some brokerages forecasting up to 35% further upside from current levels and price targets ranging between ₹305 and ₹500 for 2025. Technical indicators and historical trends show NTPC often delivers positive returns in April, with an average gain of about 3% for the month In summary, NTPC is viewed as a fundamentally sound, dividend-paying stock with moderate growth prospects and reasonable valuation. While the stock is off its recent highs, the outlook remains constructive, supported by positive earnings, stable fundamentals, and favorable long-term forecasts from analysts
NSE:NTPCLong
by KarniKripaa
1
## TORNTPHARM Price AnalysisTorrent Pharmaceuticals (TORNTPHARM) is currently trading near ₹3,254, maintaining a strong uptrend over the past several years. The stock has delivered a return of approximately 165% from July 2020 to November 2024, including a stock split, highlighting its consistent long-term growth. **Valuation and Fair Value** TORNTPHARM is trading well above its estimated intrinsic value. Independent valuations suggest a fair value in the range of ₹1,560 to ₹1,940 per share, meaning the current market price is overvalued by about 40%. The price-to-earnings (PE) ratio stands at approximately 59–66, which is significantly higher than the sector average of around 49, indicating a premium valuation. The price-to-book (PB) ratio is also elevated at 16, compared to the sector average of 6.29. **Recent Performance** The stock has shown positive momentum in the short term, with returns of 3.5% over the past week and 5.7% over the past month. Over the last year, TORNTPHARM has gained nearly 28%, and over three years, the return is more than 128%. Despite some volatility, the stock has outperformed many of its peers and the broader market. **Fundamental Trends** Torrent Pharma’s India business, which constitutes the bulk of its revenue, grew by 12% in Q3 FY25, driven by strong performance in branded generics. However, the company faces challenges in international markets, particularly the US, due to regulatory headwinds and pricing pressures. Revenue growth over the past five years has averaged 7% annually, slightly below the industry average, but net income growth has been robust at over 30% per year, outpacing peers. **Analyst Outlook** Analysts have a moderately positive outlook, with a one-year price target averaging around ₹3,600, and a range between ₹2,959 and ₹4,200 . About 68% of analysts currently rate the stock as a buy. **Dividend and Market Cap** The dividend yield is 0.86%, which is above the sector average, and the company’s market capitalization is approximately ₹1.1 lakh crore, placing it among the larger players in the Indian pharmaceutical sector. **Summary** TORNTPHARM has demonstrated strong long-term price appreciation and profitability, but it is currently trading at a significant premium to its estimated intrinsic value. Short-term technicals are mixed, with some bullish undertones, but caution is warranted due to high valuation multiples. The company’s growth is primarily driven by its domestic business, while international operations face ongoing challenges. Analyst sentiment remains positive, but the upside may be limited unless earnings growth accelerates or valuation multiples contract.
NSE:TORNTPHARMLong
by KarniKripaa
SBICARD: Monthly Pennant Breakout - How High Can It Fly?NSE:SBICARD The stock has given a pennant pattern breakout on monthly chart with good volume along with second month on consecutive buying This month's closing would be interesting to watch as it'd confirm the follow on move 916.95 / 946 / 1149 will act as strong resistance levels especially 1149 which is around it's ATH level a monthly close above it will fuel the further rally. Since it's ATH in September 2021 stock has been in a downtrend but seems like things are about to change for good SBI Cards & Payment Services is India's second-largest credit card issuer and a subsidiary of SBI. Market Position : SBI Cards is a leader in the credit card industry, holding an 18.5% market share in card-in-force and a 15.7% share in spending. You'll find them actively expanding into Tier-2 and Tier-3 cities to tap into new markets. Plus, partnerships with brands like Apple and Singapore Airlines help them attract premium customers. Recent Financials (Q3 FY25): Revenue: ₹4,767 crore (up 1% YoY). Net Profit: ₹383 crore (down 30% YoY). Net Interest Income (NII): ₹3,790 crore (down 3.5% YoY). Asset Quality: Gross NPA at 3.24%, Net NPA at 1.18%. 9-Month Performance (9MFY25): Revenue: ₹14,300 crore (up ~2% YoY). Net Profit: ₹1,200 crore (down ~25% YoY). Where is SBI Cards Headed? Management is optimistic, projecting annual revenue growth of 10%-15% over the next two years. The plan involves: Tapping into smaller cities to bring in new customers. Boosting the digital experience for seamless customer interactions. Launching exciting co-branded cards aimed at high-value users. And don't forget, potential RBI rate cuts in FY26 could lower borrowing costs and boost the bottom line.
NSE:SBICARDLong
by sandeshprabhu85
JUBLFOOD Probable price actionBased on the recent price action for Jubilant FoodWorks Ltd (JUBLFOOD), the stock shows a bullish trend in the short term: 1. The stock closed at ₹670.5 on February 14, 2025, up 1.27% from the previous close. 2. JUBLFOOD has been in an uptrend since late January 2025, rising from ₹638.65 on January 27 to the current price of ₹670.50. 3. The stock has shown strong momentum, breaking above the ₹700 level in early January before a brief pullback. 4. Recent price action indicates a recovery from the pullback, with the stock forming higher lows and higher highs since February 12, 2025. 5. The stock is trading above its 50-day moving average of ₹699.307, suggesting bullish sentiment in the medium term. 6. Volume has been above average in recent sessions, with 4,032,606 shares traded on February 14, compared to the average volume of 2,001,293. 7. The stock is showing strength relative to its 52-week range, currently trading closer to its year high of ₹796.75 than its year low of ₹421.05. However, traders should note some potential resistance levels: 1. The stock may face resistance near the ₹700 level, which it failed to hold in early February. 2. The year high of ₹796.75 could act as a strong resistance if the uptrend continues. Overall, the price action suggests a bullish short-term outlook for JUBLFOOD.
NSE:JUBLFOODLong
by KarniKripaa
AWHCL: A bullish pennant breakoutAWHCL has recently exhibited a breakout from a bullish pennant pattern on the daily chart. The breakout from the bullish pennant pattern is characterized by a significant price movement beyond the upper boundary of the pennant. This breakout is often seen as a signal of a strong buying interest and can lead to sustained upward price action. The stock has closed above the previous week's high, a critical technical level that reinforces the positive outlook. This closure suggests increased buying pressure and establishes a strong foundation for potential growth. AWHCL presents an attractive opportunity within the demand zone of 760-770. This area has historically demonstrated robust buying interest, indicating a potential reversal or support point for the stock. Based on current price action, the next discernible supply zone is projected to be around the 899 level. This zone may act as a resistance point where profit-taking could occur, thus requiring careful monitoring as the stock approaches this area. Based on the technical setup, AWHCL has the potential for an approximate 15% upside from the demand zone. A prudent stop-loss level may be below 731 to mitigate risk in case of adverse price movement. Disclaimer: The information provided in this technical analysis report is for informational and educational purposes only and should not be interpreted as financial advice. Investors are encouraged to conduct their own comprehensive research or consult with a financial advisor before making any investment decisions.
NSE:AWHCLLong
by NiftyNotions
HUGE BULLISH SIGNAL FLASING FOR BITCOINHey friends! Today, I've got an exciting idea about BTC. On the weekly time frame, BTC has clearly formed a bullish pennant pattern. If you observe the daily RSI, it has reached the oversold area, sweeping all liquidity from the market. The weekly RSI is also around the 50 level, indicating a potential bounce with hidden bullish divergence. This suggests a strong upward movement with a target of $106k! 🚀💰 #BTC #Bitcoin #Crypto #BullishPennant #RSI #HiddenBullishDivergence #CryptoTrading #TechnicalAnalysis #CryptoInvesting #MarketUpdate #CryptoMarket #BullRun #BTCto106k
BITSTAMP:BTCUSDLong
by crypto_vulture_signals
Bullish Pennant Breakout: Retest Targets $1,000 MilestoneBinance Coin ( CRYPTOCAP:BNB ) has recently formed a bullish pennant pattern, suggesting a strong potential for upward movement. This technical formation, characterized by converging trend lines following a significant price increase, indicates that the market is consolidating before potentially continuing its upward trend. The breakout from this bullish pennant has been accompanied by substantial trading volume, reinforcing the likelihood of a sustained move higher. With the retest of the breakout level successfully holding, the technical outlook is bullish, pointing to a potential target of $1,000. Achieving this target would represent a significant 68% return from the current price level, offering a promising opportunity for traders and investors. Key factors to watch include the continuation of high trading volume and maintaining the breakout level support, which will be crucial in confirming the strength of this bullish move towards the $1,000 target.
Long
by crypto_vulture_signals
#BTC/USDT Primed for Breakout#BTC/USDT Technical Analysis: Two Potential Scenarios Scenario 1: Symmetrical Triangle Formation - **Current Pattern**: BTC/USDT is forming a symmetrical triangle, a common continuation pattern that usually indicates a period of consolidation before the price moves in the direction of the previous trend. - **Upward Breakout**: If BTC breaks above the upper trendline of the triangle around $75,000, this could indicate a bullish continuation. Such a breakout would likely attract significant buying interest, potentially driving the price higher and grabbing liquidity above this key level. - **Downside Risk**: Conversely, if BTC breaks below the lower trendline, the next major support level is around $61,000. This would suggest a bearish scenario where the price could decline further, testing this support level. Scenario 2: Bullish Pennant Formation - **Current Pattern**: BTC/USDT is also forming a bullish pennant, another continuation pattern that often occurs after a strong upward move. This pattern indicates a brief consolidation before the price continues in the direction of the prevailing trend. - **Bullish Breakout**: If BTC breaks out from the pennant formation with strong volume and momentum, we could expect a significant upward move. The target for this breakout is around $85,000, based on the height of the initial flagpole leading into the pennant formation. - **Confirmation**: For this bullish scenario to be validated, the breakout needs to occur with substantial volume, confirming the strength of the move.
BINANCE:BTCUSD.P
by crypto_vulture_signals
HFCL - Breakout from pennant - Continuation b.o.The analysis is done on Weekly TF hence price may take few weeks to few months in order to reach the targets. Trade setup is explained in image itself. This is a continuation breakout chart. When price comes out of such narrow zone on higher timeframe, chances of such breakouts being successful increases manifold. The above analysis is purely for educational purpose. Traders must do their own study & follow risk management before entering into any trade Checkout my other ideas to understand how one can earn from stock markets with simple trade setups. Feel Free to comment below this or connect with me for any query or suggestion regarding this stock or Price Action Analysis.
NSE:HFCLLong
by TradewithAditya
Falling Trendline b/o in kcp ltd with gcrossoverFalling Trendline breakout is developing on weekly chart of NSE:KCP One lookinto it to buy the scrip at cmp with a stop loss of 100 for the targets of 122, 133, 144 respectively. The stock has given the golden crossover(Bullish Signal) and 5wema is above 44wema. Exit the position if the stop loss triggered on Weekly closing basis. DO YOU WANT ALL MY RESEARCH FOR FREE THEN DON'T FORGET TO FOLLOW ME. I AM EAGERLY WAITING FOR YOU COMMENTS ON THE STUDY... Disclaimer: Content shared is for information and education purposes only and should not be treated as investment or trading advice. Please do your own analysis or take independent professional financial advice before making any investments based on your own personal circumstances. Investment in securities are subject to market risks, please carry out your due diligence before investing. And last but not the least, past performance is not indicative of future returns.
NSE:KCPLong
by raigvivek
1